Research Analysts Issue Forecasts for Precigen Q1 Earnings

Precigen, Inc. (NASDAQ:PGEN) – HC Wainwright reduced their Q1 2025 EPS estimates for shares of Precigen in a note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn ($0.08) per share for the quarter, down from their prior estimate of ($0.04). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at ($0.06) EPS.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The company had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $1.30 million.

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Precigen presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Precigen Trading Down 6.0 %

PGEN opened at $1.71 on Monday. The stock’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $1.17. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17. The stock has a market cap of $502.81 million, a PE ratio of -3.11 and a beta of 1.58.

Institutional Trading of Precigen

Several hedge funds have recently added to or reduced their stakes in PGEN. BNP Paribas Financial Markets acquired a new position in Precigen in the 4th quarter valued at $27,000. Envestnet Asset Management Inc. grew its stake in shares of Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 5,915 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Precigen in the fourth quarter valued at about $35,000. Stifel Financial Corp increased its position in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 15,680 shares during the period. Finally, RPO LLC acquired a new stake in Precigen in the 4th quarter worth about $47,000. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.